EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Roles of regulatory T cells in cancer immunity

Yoshiko Takeuchi, Hiroyoshi Nishikawa

International Immunology · 01.08.2016 · 28 (8) · 401-409

DOI: 10.1093/intimm/dxw025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunology, online erschienen am 09.05.2016. Verfasst von Yoshiko Takeuchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology, EPOC, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan and. Die Arbeit wurde bisher 476-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD4 + regulatory T cells (T regs ) expressing the transcription factor FoxP3 are highly immune suppressive and play central roles in the maintenance of self-tolerance and immune homeostasis, yet in malignant tumors they promote tumor progression by suppressing effective antitumor immunity. Indeed, higher infiltration by T regs is observed in tumor tissues, and their depletion augments antitumor immune responses in animal models. Additionally, increased numbers of T regs and, in particular, decreased ratios of CD8 + T cells to T regs among tumor-infiltrating lymphocytes are correlated with poor prognosis in various types of human cancers. The recent success of cancer immunotherapy represented by immune checkpoint blockade has provided a new insight in cancer treatment, yet more than half of the treated patients did not experience clinical benefits. Identifying biomarkers that predict clinical responses and developing novel immunotherapies are therefore urgently required. Cancer patients whose tumors contain a large number of neoantigens stemming from gene mutations, which have not been previously recognized by the immune system, provoke strong antitumor T-cell responses associated with clinical responses following immune checkpoint blockade, depending on the resistance to T reg -mediated suppression. Thus, integration of a strategy restricting T reg -mediated immune suppression may expand the therapeutic spectrum of cancer immunotherapy towards patients with a lower number of neoantigens. In this review, we address the current understanding of T reg -mediated immune suppressive mechanisms in cancer, the involvement of T regs in cancer immunotherapy, and strategies for effective and tolerable T reg -targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8 AntigensCancer VaccinesForkhead Transcription FactorsHumansImmunity, CellularImmunosuppression TherapyImmunotherapyLymphocyte ActivationNeoplasmsT-Lymphocytes, CytotoxicT-Lymphocytes, RegulatoryTumor Escape

Stichwörter der Autor:innen

Treg-targeted therapyimmune checkpoint inhibitorsimmune suppression

Substanzen

CD8 AntigensCancer VaccinesFOXP3 protein, humanForkhead Transcription Factors

Autor:innen und Institutionen

  • Division of Cancer Immunology, EPOC, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan and.
  • Division of Cancer Immunology, EPOC, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan and Department of Immunology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 4…

Zitieren

APA

Takeuchi, Y., & Nishikawa, H. (2016). Roles of regulatory T cells in cancer immunity. International Immunology, 28(8), 401-409. https://doi.org/10.1093/intimm/dxw025

Vancouver

Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. International Immunology. 2016;28(8):401-409. doi:10.1093/intimm/dxw025

BibTeX
@article{Takeuchi2016,
  author = {Takeuchi, Yoshiko and Nishikawa, Hiroyoshi},
  title = {Roles of regulatory T cells in cancer immunity},
  journal = {International Immunology},
  year = {2016},
  volume = {28},
  number = {8},
  pages = {401--409},
  doi = {10.1093/intimm/dxw025}
}
Kostenlos starten →